PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.
XEN-D0501, the recently purchased, safe clinical development candidate, will enter the first clinical trials in type-2 diabetic patients in 2017.

Pila_Logo_Orang-2x

Investor presentation at ‘Next Big Thing’ (by Blasieholmen Investment Group)
Moderna Museet, Stockholm, Sweden

Watch the presentation here
Direct link to presentation here

(02-Dec-2016)
pila_modernamuseet
Meet us at
Prague

Dr. Dorte X. Gram has accepted to give a talk entitled: ‘If I’m right, this could be a really big thing! – daring to challenge status-quo in diabetes treatment’

Prague Summer School – Advances in Drug Discovery
September 4-8, 2017
Prague, Czech Republic
praguesummerschool.cz

easd

European Association for the Study of Diabetes

Lisboa, Portugal
September 11-15, 2017
easd.org

NLS_Days_2017_Main_Signature_w_date_Landscape_yellow

Nordic Life Science Days

Malmö, Sweden — Copenhagen, Denmark
September 12-14, 2017
nlsdays.com

BioJapan

BioJapan
Regenerative Medicine Japan 2017

Pacifico Yokohama, Japan
October 11-13, 2017

BioJapan
Regenerative Medicine Japan 2017

Interview
affarslivet

We are proud to be on the cover of the June 2017 issue of Affärslivet Norden, Medicine and Science magazine as focuses on innovation.

Read the article in Swedish here
Read the magazine in Swedish here

(22-June-2017)
DorteX Gram

“Min uppfinning kom och hämtade tillbaka mig”
Dr. Dorte X. Gram, CEO of PILA Pharma was interviewed by Sydsvenskan, Sweden.

Read the article in Swedish here

(04-Dec-2016)
01-omslag-nordic-life-science-nr-03-2016

We are proud to be on the cover of the September 2016 issue of Nordic Life Science Magazine as representatives of Nordic Life Science companies.

Read the article here
Read the magazine here

(09-Sep-2016)

At BioEurope Spring in Stockholm in April 2016 Dr. Dorte X. Gram, CEO of PILA Pharma was interviewed by the organizers about the current status and our plans going forward.

Please find the links below:
partnering360.com

(08-Apr-2016)